2011 Research Annual Report

E-mail this page

(All fields required)

Please enter a valid email.

Please enter your name.

Please enter a valid email.

Molecular Cardiovascular Biology

 

Division Data Summary

Research and Training Details

Number of Faculty9
Number of Joint Appointment Faculty1
Number of Research Fellows21
Number of Research Students13
Number of Support Personnel18
Direct Annual Grant Support$4,676,640
Direct Annual Industry Support$5,000
Peer Reviewed Publications49

Significant Publications

Combs MD, Braitsch CM, Lange AW, James JF, Yutzey KE. NFATC1 promotes epicardium-derived cell invasion into myocardium. Development. [Research Support, N.I.H., Extramural]. 138(9):1747-57. May, 2011.
During development, epicardial cells on the surface of the heart invade the myocardium to form the coronary blood vessels and fibrous connective tissue.  Michelle Combs, a graduate student in Dr. Katherine Yutzey's lab, discovered that the transcription factor NFATc1 is required for the myocardial invasion of epicardial cells.  Studies in mice and chicken embryos demonstrate that loss of NFATc1 in epicardial cells prevents myocardial invasion, thus inhibiting the development of the coronary vessels and fibrous connective tissue of the heart.  The invasion of myocardium by epicardial-derived cells is likely mediated by the NFATc1 downstream target gene cathepsin K, that encodes an extracellular matrix-degrading enzyme.  Recently, epicardial cells have been identified as a source of regenerative cells in cardiovascular disease.  Therefore, manipulation of the NFATc1 pathway could be exploited to promote the invasion or investment of progenitor cells in diseased hearts.
Goonasekera SA, Lam CK, Millay DP, Sargent MA, Hajjar RJ, Kranias EG, Molkentin JD. Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle. The Journal of clinical investigation. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 121(3):1044-52. Mar, 2011.
The Molkentin laboratory published a paper in The Journal of Clinical Investigation this past year in which they identified an entirely novel strategy for treating muscular dystrophy.  Mice engineered to overexpress the protein SERCA in skeletal muscle showed substantial protection from mutations that normally lead to muscular dystrophy.  Dr. Molkentin and colleagues also showed a gene therapy approach whereby transfer of the SERCA gene in skeletal muscle immediately corrected disease due to a Duchenne-like mutation in mice.  These results suggest novel approaches to mitigate the underlying molecular defects that initiate skeletal muscle and cardiac cellular necrosis in muscular dystrophy by enhancing SERCA activity and/or expression.  The laboratory is currently working on novel SERCA activating drugs that could also be employed to treat this disease in the near future.
Heineke J, Auger-Messier M, Correll RN, Xu J, Benard MJ, Yuan W, Drexler H, Parise LV, Molkentin JD. CIB1 is a regulator of pathological cardiac hypertrophy.Nature medicine. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 16(8):872-9. Aug, 2010.
This paper from the Molkentin laboratory identified a novel regulatory pathway that functions through the intracellular phosphatase calcineurin to regulate how the heart hypertrophies in response to disease inducing stimuli.  The protein CIB1 was shown to modulate calcineurin signaling at the plasma membrane, and inhibition of CIB1 function reduced cardiac hypertrophy through calcineurin.  This research suggests novel treatment angles for reducing pathological manifestations to the heart in response to disease inducing states.
Hinton RB, Adelman-Brown J, Witt S, Krishnamurthy VK, Osinska H, Sakthivel B, James JF, Li DY, Narmoneva DA, Mecham RP, Benson DW. Elastin haploinsufficiency results in progressive aortic valve malformation and latent valve disease in a mouse model. Circulation research. [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 107(4):549-57. Aug, 2010.
This paper describes a mouse model of latent and progressive aortic valve disease. Elastin (Eln) haploinsufficiency was induced by gene targeting. Eln null mice died in the perinatal period due to severe arterial obstruction, but the Eln haploinsufficient mice (Eln+/-) had normal longevity. Valvular intersitial cell activation and TGFb receptor 1 downregulation is at least in part responsible for the pathogenesis in this model, resulting in hyperproliferation and maladaptive extracellular matrix remodeling. The valve cusp histopathology of the Eln+/- mice mimics the findings of human degenerative aortic valve disease, thus these mice thus have the potential of contributing to the development of novel therapeutics for patients with aortic valve disease.

Division Highlights

Joshua Waxman, PhD

The Waxman lab’s recent work has focused on factors that affect cardiac progenitor specification and indicates that cardiac and forelimb progenitors interact, helping to direct each ones’ development. Specifically, we have found that retinoic acid signaling acting on forelimb progenitors impacts fibroblast growth factor signaling, which acts on cardiac progenitors. Together, these interactions allow proper specification of these different fields.  We think elucidating these interactions will allow us to understand developmental syndromes that result in both heart and forelimb defects.

Division Collaboration

Human Genetics » Teresa Smolarek, PhD; Sarah Zimmerman, PhD
Study of microarray abnormalities in patients with cardiovascular malformations, funded by a grant through the March of Dimes.
Allergy and Immunology; Gastroenterology » Marc Rothenberg, MD, PhD; Philip Putnam, MD; James Franciosi, MD, MS, MSCE
TGF beta dysregulation: understanding the relationship in patients with eosionophilic esophagitis and connective tissue abnormalities.
Biomedical Informatics » Bruce Aronow, PhD
Use of systems biology to identify genetic regulatory networks for cardiomyopathy.

Faculty Members

Jeffrey Robbins, PhD, Professor
Executive Co-Director, The Heart Institute
Associate Chair of the CCHMC
Endowed Chair for Molecular Cardiovascular Biology
Research Interests Mechanisms of Normal and Abnormal Cardiovascular function
James Gulick, MS, Instructor
Research Interests Molecular interactions between certain cardiac contractile proteins and how such interactions can be altered by mutations that are associated with cardiomyopathies
Jeanne James, MD, Associate Professor
Director, Mouse Echocardiography Core
Research Interests Manifestations and etiologies of misfolded protein response and echocardiography
Zaza Khuchua, PhD, Associate Professor
Research Interests Congenital cardiac disorders caused by inborn errors in mitochondrial energy-producing enzymes, and model systems to study molecular mechanisms of these diseases
Marjorie Maillet, PhD, Instructor
Research Interests Understanding signaling pathways that lead to heart disease
Jeffery Molkentin, PhD, Professor
Howard Hughes Medical Institute Investigator
Research Interests Molecular pathways that underlie heart disease and muscular dystrophy
Stephanie Ware, MD, PhD, Associate Professor
Director of Research and Development, Associate Medical Director, The Heart Institute Diagnostic Laboratory
Co-Director, Cardiovascular Genetics
Research Interests Genetics of pediatric heart disease
Joshua Waxman, PhD, Assistant Professor
Research Interests Molecular Genetics of Heart Development
Katherine Yutzey, PhD, Professor
Research Interests Heart development and disease mechanisms

Joint Appointment Faculty Members

D Woodrow Benson, MD, PhD, Professor
Cardiology
Research Interests Genetic basis of pediatric heart disease

Trainees

  • Federica Accornero, PhD, University of Turin, Italy
  • Mannix Auger-Messier, PhD, University of Sherbrooke, Canada
  • Md. Shenuarin Bhuiyan, PhD, Tohoku University, Japan
  • Caitlin Braitsch, BS, Xavier University
  • Adam Burr, BS, University of Minnesota, Twin Cities
  • Ashley Cast, BA, Augustana College
  • Santanu Chakraborty, PhD, Miami University
  • Michelle Combs, BS, Quincy University
  • Robert Nathan Correll, PhD, University of Kentucky
  • Jason Cowan, MS, University of Miami
  • Enrico D'Aniello, PhD, Marine Zoological Station Anton Dohrn, Italy
  • Jennifer Davis, PhD, Univeristy of Michigan, Ann Arbor
  • Tracy Dohn, BS, Wittenberg University
  • Petra Eder, PhD, University of Graz, Austria
  • John Elrod, PhD, Albert Einstein College of Medicine
  • Ambrose Goonasekera, PhD, University of Rochester
  • Manish Gupta, PhD, University of Cincinnati
  • Mary Lee, MS, Ball State University
  • Jason Karch, BA, Dakota Wesleyan University
  • Izhak Kehat, PhD, Technion-Israel Institute of Technology, Isreal
  • Jennifer Kwong, PhD, Weill Medical College of Cornell University
  • Ruijie Liu, PhD, University of Illinois at Urbana Champaign
  • Jeffrey Lynch, PhD, University of Alberta, Canada
  • Patrick McLendon, PhD, Virginia Polytechnical Institute and State University
  • Timothy Mead, BS, University of Dayton
  • Diana Nardini, BS, College of Mount St. Joseph
  • Ariel Rydeen, BS, University of Minnesota
  • Arunima Sengupta, PhD, Miami University
  • Mardi Sutherland, BS, University of Massachusetts, Boston
  • Muhammad Tariq, PhD, Quaid-I-Azam University, Pakistan
  • Jop van Berlo, MD, PhD, University Hospital Maastricht, Netherlands
  • Davy Vanhoutte, PhD, University of Leuven, Belgium
  • Elaine Wirrig, PhD, Medical University of South Carolina
  • Erin Wissing, BA, DePauw University
Return to Top

Division Publications

  1. Acehan D, Vaz F, Houtkooper RH, James J, Moore V, Tokunaga C, Kulik W, Wansapura J, Toth MJ, Strauss A, Khuchua Z. Cardiac and skeletal muscle defects in a mouse model of human Barth syndrome. The Journal of biological chemistry. 2011; 286:899-908.
  2. Bolli R, Stein AB, Guo Y, Wang OL, Rokosh G, Dawn B, Molkentin JD, Sanganalmath SK, Zhu Y, Xuan YT. A murine model of inducible, cardiac-specific deletion of STAT3: its use to determine the role of STAT3 in the upregulation of cardioprotective proteins by ischemic preconditioning. Journal of molecular and cellular cardiology. 2011; 50:589-97.
  3. Breitbart A, Auger-Messier M, Molkentin JD, Heineke J. Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. American journal of physiology. Heart and circulatory physiology. 2011; 300:H1973-82.
  4. Chakraborty S, Wirrig EE, Hinton RB, Merrill WH, Spicer DB, Yutzey KE. Twist1 promotes heart valve cell proliferation and extracellular matrix gene expression during development in vivo and is expressed in human diseased aortic valves. Developmental biology. 2010; 347:167-79.
  5. Ch'en IL, Tsau JS, Molkentin JD, Komatsu M, Hedrick SM. Mechanisms of necroptosis in T cells. The Journal of experimental medicine. 2011; 208:633-41.
  6. Chen X, Nakayama H, Zhang X, Ai X, Harris DM, Tang M, Zhang H, Szeto C, Stockbower K, Berretta RM, Eckhart AD, Koch WJ, Molkentin JD, Houser SR. Calcium influx through Cav1.2 is a proximal signal for pathological cardiomyocyte hypertrophy. Journal of molecular and cellular cardiology. 2011; 50:460-70.
  7. Combs MD, Braitsch CM, Lange AW, James JF, Yutzey KE. NFATC1 promotes epicardium-derived cell invasion into myocardium. Development. 2011; 138:1747-57.
  8. Czosek RJ, Haaning A, Ware SM. A mouse model of conduction system patterning abnormalities in heterotaxy syndrome. Pediatric research. 2010; 68:275-80.
  9. Eder P, Molkentin JD. TRPC channels as effectors of cardiac hypertrophy. Circulation research. 2011; 108:265-72.
  10. Elrod JW, Wong R, Mishra S, Vagnozzi RJ, Sakthievel B, Goonasekera SA, Karch J, Gabel S, Farber J, Force T, Brown JH, Murphy E, Molkentin JD. Cyclophilin D controls mitochondrial pore-dependent Ca(2+) exchange, metabolic flexibility, and propensity for heart failure in mice. The Journal of clinical investigation. 2010; 120:3680-7.
  11. Fakhro KA, Choi M, Ware SM, Belmont JW, Towbin JA, Lifton RP, Khokha MK, Brueckner M. Rare copy number variations in congenital heart disease patients identify unique genes in left-right patterning. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:2915-20.
  12. Force T, Bonow RO, Houser SR, Solaro RJ, Hershberger RE, Adhikari B, Anderson ME, Boineau R, Byrne BJ, Cappola TP, Kalluri R, LeWinter MM, Maron MS, Molkentin JD, Ommen SR, Regnier M, Tang WH, Tian R, Konstam MA, Maron BJ, Seidman CE. Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation. 2010; 122:1130-3.
  13. Froese N, Kattih B, Breitbart A, Grund A, Geffers R, Molkentin JD, Kispert A, Wollert KC, Drexler H, Heineke J. GATA6 promotes angiogenic function and survival in endothelial cells by suppression of autocrine transforming growth factor beta/activin receptor-like kinase 5 signaling. The Journal of biological chemistry. 2011; 286:5680-90.
  14. Gilio K, Harper MT, Cosemans JM, Konopatskaya O, Munnix IC, Prinzen L, Leitges M, Liu Q, Molkentin JD, Heemskerk JW, Poole AW. Functional divergence of platelet protein kinase C (PKC) isoforms in thrombus formation on collagen. The Journal of biological chemistry. 2010; 285:23410-9.
  15. Goonasekera SA, Lam CK, Millay DP, Sargent MA, Hajjar RJ, Kranias EG, Molkentin JD. Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle. The Journal of clinical investigation. 2011; 121:1044-52.
  16. Harper MT, Molkentin JD, Poole AW. Protein kinase C alpha enhances sodium-calcium exchange during store-operated calcium entry in mouse platelets. Cell calcium. 2010; 48:333-40.
  17. Heineke J, Auger-Messier M, Correll RN, Xu J, Benard MJ, Yuan W, Drexler H, Parise LV, Molkentin JD. CIB1 is a regulator of pathological cardiac hypertrophy. Nature medicine. 2010; 16:872-9.
  18. Hinton RB, Adelman-Brown J, Witt S, Krishnamurthy VK, Osinska H, Sakthivel B, James JF, Li DY, Narmoneva DA, Mecham RP, Benson DW. Elastin haploinsufficiency results in progressive aortic valve malformation and latent valve disease in a mouse model. Circulation research. 2010; 107:549-57.
  19. Hinton RB, Michelfelder EC, Marino BS, Bove KE, Ware SM. A fetus with hypertrophic cardiomyopathy, restrictive, and single-ventricle physiology, and a beta-myosin heavy chain mutation. The Journal of pediatrics. 2010; 157:164-6.
  20. Hinton RB, Yutzey KE. Heart valve structure and function in development and disease. Annual review of physiology. 2011; 73:29-46.
  21. James J, Robbins J. Signaling and myosin-binding protein C. The Journal of biological chemistry. 2011; 286:9913-9.
  22. Kehat I, Accornero F, Aronow BJ, Molkentin JD. Modulation of chromatin position and gene expression by HDAC4 interaction with nucleoporins. The Journal of cell biology. 2011; 193:21-9.
  23. Kehat I, Davis J, Tiburcy M, Accornero F, Saba-El-Leil MK, Maillet M, York AJ, Lorenz JN, Zimmermann WH, Meloche S, Molkentin JD. Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circulation research. 2011; 108:176-83.
  24. Kehat I, Molkentin JD. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation. 2010; 122:2727-35.
  25. Korf-Klingebiel M, Kempf T, Schluter KD, Willenbockel C, Brod T, Heineke J, Schmidt VJ, Jantzen F, Brandes RP, Sugden PH, Drexler H, Molkentin JD, Wollert KC. Conditional transgenic expression of fibroblast growth factor 9 in the adult mouse heart reduces heart failure mortality after myocardial infarction. Circulation. 2011; 123:504-14.
  26. Lincoln J, Yutzey KE. Molecular and developmental mechanisms of congenital heart valve disease. Birth defects research. Part A, Clinical and molecular teratology. 2011; 91:526-34.
  27. Maloyan A, Robbins J. Autophagy in desmin-related cardiomyopathy: Thoughts at the halfway point. Autophagy. 2010; 6:665-666.
  28. Meissner M, Weissgerber P, Londono JE, Prenen J, Link S, Ruppenthal S, Molkentin JD, Lipp P, Nilius B, Freichel M, Flockerzi V. Moderate calcium channel dysfunction in adult mice with inducible cardiomyocyte-specific excision of the cacnb2 gene. The Journal of biological chemistry. 2011; 286:15875-82.
  29. Nakayama H, Bodi I, Maillet M, DeSantiago J, Domeier TL, Mikoshiba K, Lorenz JN, Blatter LA, Bers DM, Molkentin JD. The IP3 receptor regulates cardiac hypertrophy in response to select stimuli. Circulation research. 2010; 107:659-66.
  30. Qian L, Wythe JD, Liu J, Cartry J, Vogler G, Mohapatra B, Otway RT, Huang Y, King IN, Maillet M, Zheng Y, Crawley T, Taghli-Lamallem O, Semsarian C, Dunwoodie S, Winlaw D, Harvey RP, Fatkin D, Towbin JA, Molkentin JD, Srivastava D, Ocorr K, Bruneau BG, Bodmer R. Tinman/Nkx2-5 acts via miR-1 and upstream of Cdc42 to regulate heart function across species. The Journal of cell biology. 2011; 193:1181-96.
  31. Sengupta A, Molkentin JD, Paik JH, DePinho RA, Yutzey KE. FoxO transcription factors promote cardiomyocyte survival upon induction of oxidative stress. The Journal of biological chemistry. 2011; 286:7468-78.
  32. Spicer RL, Ware SM. Diseases of the Myocardium. Nelson textbook of pediatrics. Philadelphia, PA: Elsevier/Saunders; 2011: 1 online resource (p.). .
  33. Spicer RL, Ware SM. Diseases of the Pericardium. Nelson textbook of pediatrics. Philadelphia, PA: Elsevier/Saunders; 2011: 1 online resource (p.). .
  34. Spicer RL, Ware SM. Tumors of the Heart. Nelson textbook of pediatrics. Philadelphia, PA: Elsevier/Saunders; 2011: 1 online resource (p.). .
  35. Stanley BA, Graham DR, James J, Mitsak M, Tarwater PM, Robbins J, Van Eyk JE. Altered myofilament stoichiometry in response to heart failure in a cardioprotective alpha-myosin heavy chain transgenic rabbit model. Proteomics. Clinical applications. 2011; 5:147-58.
  36. Stefater JA, 3rd, Lewkowich I, Rao S, Mariggi G, Carpenter AC, Burr AR, Fan J, Ajima R, Molkentin JD, Williams BO, Wills-Karp M, Pollard JW, Yamaguchi T, Ferrara N, Gerhardt H, Lang RA. Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells. Nature. 2011; 474:511-5.
  37. Sugden PH, Markou T, Fuller SJ, Tham el L, Molkentin JD, Paterson HF, Clerk A. Monophosphothreonyl extracellular signal-regulated kinases 1 and 2 (ERK1/2) are formed endogenously in intact cardiac myocytes and are enzymically active. Cellular signalling. 2011; 23:468-77.
  38. Sun T, Wu XS, Xu J, McNeil BD, Pang ZP, Yang W, Bai L, Qadri S, Molkentin JD, Yue DT, Wu LG. The role of calcium/calmodulin-activated calcineurin in rapid and slow endocytosis at central synapses. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2010; 30:11838-47.
  39. Tang M, Li J, Huang W, Su H, Liang Q, Tian Z, Horak KM, Molkentin JD, Wang X. Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodeling of stressed mouse hearts. Cardiovascular research. 2010; 88:424-33.
  40. Tang M, Zhang X, Li Y, Guan Y, Ai X, Szeto C, Nakayama H, Zhang H, Ge S, Molkentin JD, Houser SR, Chen X. Enhanced basal contractility but reduced excitation-contraction coupling efficiency and beta-adrenergic reserve of hearts with increased Cav1.2 activity. American journal of physiology. Heart and circulatory physiology. 2010; 299:H519-28.
  41. van Berlo JH, Elrod JW, van den Hoogenhof MM, York AJ, Aronow BJ, Duncan SA, Molkentin JD. The transcription factor GATA-6 regulates pathological cardiac hypertrophy. Circulation research. 2010; 107:1032-40.
  42. Wansapura JP, Millay DP, Dunn RS, Molkentin JD, Benson DW. Magnetic resonance imaging assessment of cardiac dysfunction in delta-sarcoglycan null mice. Neuromuscular disorders : NMD. 2011; 21:68-73.
  43. Ware SM. Genetic diagnosis in pediatric cardiomyopathy: clinical application and research perspectives. Progress in pediatric cardiology. 2011; 31:99-102.
  44. Waxman JS, Yelon D. Zebrafish retinoic acid receptors function as context-dependent transcriptional activators. Developmental biology. 2011; 352:128-40.
  45. Wirrig EE, Hinton RB, Yutzey KE. Differential expression of cartilage and bone-related proteins in pediatric and adult diseased aortic valves. Journal of molecular and cellular cardiology. 2011; 50:561-9.
  46. Wirrig EE, Yutzey KE. Transcriptional regulation of heart valve development and disease. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology. 2011; 20:162-7.
  47. Wissing ER, Millay DP, Vuagniaux G, Molkentin JD. Debio-025 is more effective than prednisone in reducing muscular pathology in mdx mice. Neuromuscular disorders : NMD. 2010; 20:753-60.
  48. Yamaguchi N, Chakraborty A, Pasek DA, Molkentin JD, Meissner G. Dysfunctional ryanodine receptor and cardiac hypertrophy: role of signaling molecules. American journal of physiology. Heart and circulatory physiology. 2011; 300:H2187-95.
  49. Zhang H, Chen X, Gao E, MacDonnell SM, Wang W, Kolpakov M, Nakayama H, Zhang X, Jaleel N, Harris DM, Li Y, Tang M, Berretta R, Leri A, Kajstura J, Sabri A, Koch WJ, Molkentin JD, Houser SR. Increasing cardiac contractility after myocardial infarction exacerbates cardiac injury and pump dysfunction. Circulation research. 2010; 107:800-9.
Return to Top

Grants, Contracts, and Industry Agreements

Grant and Contract AwardsAnnual Direct / Project Period Direct

Braitsch, C

Tbx18 Regulation of Epicardial-Derived Cell Proliferation, Migration and Differentiation in Cardiac Development
07/01/09-06/30/11$23,000

Correll, R

Regulation of Cardiac Gene Expression by the L-type Calcium Channel, CaV1.2
F32 HL 09755109/07/09-09/06/12$50,474

Davis, J

The Non-Hypertrophic Role of Calcineurin in Regulating Cardiac Structure-Function
F32 HL 09535312/15/08-12/14/11$52,154

Karch, J

The Role of Bax and Bak in Necrotic Cell Death
07/01/10-06/30/12$23,000

Khuchua, Z

The shRNA-Mediated Tafazzin Knockdown Mouse Model
01/01/10-12/31/11$16,361

Krishnamurthy, V

Valve Tissue Mechanics and Cell Phenotype in a Mouse Model of Aortic Valve Disease
07/01/09-06/30/11$23,000

Maillet, M

Role of IP-3 Mediated Calcium Release in Cardiac Hypertrophic Cardiomyopathy
R21 HL 09718604/15/10-03/31/12$125,000

Molkentin, J

Calcium as a Molecular Signal in the Heart
R01 HL 08931208/15/07-06/30/12$239,303
Cardiac Hypertrophic Intracellular Signaling Pathways
R01 HL 06292702/01/09-12/31/13$250,000
Molecular Pathways Controlling Cardiac Gene Expression
R37 HL 06056207/01/08-06/30/13$250,000
Thrombospondin 4 Regulates Adaptive ER Stress Response
R01 HL 10592401/01/11-12/31/11$315,000

Razzaque, A

Cardiomyopathic Mechanisms in Pediatric Congenital Disease
07/01/10-06/30/12$43,000

Robbins, J

Cardiac Myosin Binding Protein-C: Structure, Function and Regulation
P01 HL 05940802/01/10-01/31/15$356,105
Nikon A1 Confocal Microscope
S10 RR 02701407/01/10-06/30/11$388,205
Signaling Processes Underlying Cardiovascular Function
P01 HL 06977901/11/08-12/31/12$1,219,260

Sengupta, A

URC Postdoctoral Fellow Research Grant
01/01/11-12/31/11$5,000

van Berlo, J

GATA-6 Function is Crucial for Cardiac Hypertrophy to Prevent Heart Failure
07/01/10-06/30/12$43,000

Ware, S

Role of the Embryonic Node in Cardiac Development and Congenital Heart Disease
R01 HL 08863904/01/07-03/31/12$250,000
Uncovering Novel Genetic Causes and Risk in Congenital Heart Disease Patients
100849607/01/09-06/30/14$75,000
Genetic Causes of Congenital Heart Defects
06/01/10-05/31/13$93,866

Waxman, J

Elucidation of Molecular Networks Required to Limit Cardiac Cell Number
R00 HL 09112607/15/10-05/31/13$163,368
Illumination of Mechanisms Controlling Atrial Cell Formation
02/01/11-01/31/13$69,327

Yutzey, K

Notch Signaling in Heart Valve Development and Disease
R01 HL 09431907/01/09-06/30/11$308,217
The Function of Notch1 in Heart Valve Development
07/01/09-06/30/11$23,000
Twist 1 Regulation of Valve Progenitors
R01 HL 08271607/01/10-05/31/15$250,000
Weinstein Cardiovascular Development Conference 2011
04/01/11-09/30/11$2,000
Student Undergraduate Research Fellowships
06/01/10-05/31/12$20,000
Current Year Direct$4,676,640
Industry Contracts

Yutzey

$5,000
Current Year Direct Receipts$5,000
Total$4,681,640
Return to Top
Please give to Cincinnati Children's.
US News 2013 FooterBest Places to Work Logo

3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900

New to Cincinnati Children’s or live outside of the tri-state area? 1-877-881-8479

© 1999-2013 Cincinnati Children's Hospital Medical Center